BCI-Sonics (华超神控)

BCI-Sonics operates at the intersection of non-invasive brain-computer interfaces, therapeutic neuromodulation, medical imaging, and artificial intelligence. Its primary differentiation is the use of low-intensity transcranial focused ultrasound rather than implanted electrodes, positioning it closer to non-invasive neuromodulation companies than to invasive BCI developers such as Neuralink or Synchron. The company’s stated technical approach combines adaptive acoustic-field correction, physics-informed neural networks, patient-specific treatment planning, and closed-loop EEG or passive cavitation monitoring. That combination addresses two key constraints in focused ultrasound: compensating for skull-induced distortion and maintaining treatment feedback and safety. Its proposed ability to target both deep nuclei and superficial cortical regions also broadens the potential application set beyond conventional cortical stimulation. Compared with focused-ultrasound specialists such as Insightec, BCI-Sonics emphasizes an AI-defined BCI and closed-loop platform rather than presenting itself solely as a therapeutic ultrasound-device company.

BCI-Sonics has progressed rapidly from its 2025 founding to two disclosed financing events in 2026. The CNY 100 million angel round announced on Jun 8, 2026 established initial institutional backing from Delian Capital, Matrix Partners China, and Tao Capital. The CNY 200 million round announced on Sep 22, 2026 more than doubled the capital raised in the earlier round and brought total funding to approximately $44.6 million. The financing progression suggests a shift from initial platform development toward scaling technical teams and advancing therapeutic applications. Hiring activity in acoustics, neuroengineering, and AI algorithms supports that interpretation: the company appears to be building the multidisciplinary capabilities required to move from acoustic hardware and modeling into integrated treatment workflows. Its technology roadmap includes automated medical-image segmentation, Scan & Treat workflows, personalized protocol generation, and closed-loop monitoring, all of which could become important inflection points if translated into validated clinical systems. At present, there is no disclosed revenue, regulatory approval, clinical-trial outcome, or product launch schedule, so the next measurable growth indicators will likely be hiring execution, clinical validation, and regulatory progress.